ReviewMedical oncology (Northwood, London, England)2010
Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.
Review in Medical oncology (Northwood, London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013Trial
- Epigenetic drugs induce the potency of classic chemotherapy, suppress post-treatment re-growth of breast cancer, but preserve the wound healing ability of stem cells.Cancer biology & therapy · 2022Article
- SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.Frontiers in immunology · 2022Article
- eEF2 kinase mediated autophagy as a potential therapeutic target for paclitaxel-resistant triple-negative breast cancer.Annals of translational medicine · 2019Article
- Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.BMC cancer · 2018Article
- Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.BMC cancer · 2016Article
- Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.Journal of nanoscience and nanotechnology · 2015Article
- Neoadjuvant therapy in the treatment of breast cancer.Surgical oncology clinics of North America · 2014Review
- Downregulation of BCSG1 may correlate with better outcome of neoadjuvant chemotherapy for triple-negative breast cancer.Oncology letters · 2012Article
- Triple-negative and basal-like breast cancer: implications for oncologists.Current oncology (Toronto, Ont.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with breast cancer who achieve a complete pathologic response (pCR) after preoperative (neoadjuvant) chemotherapy have an improved prognosis compared to those with residual disease; pCR being a good surrogate of long-term survival and cure from breast cancer. Despite their relative chemosensitivity, less than 25% of all patients with HER2/neu negative (0-2+), and hormone receptors (HR) negative tumors, so-called "Triple Negative" breast cancer (TNBC) treated with standard preoperative chemotherapy achieve pCR. Among patients with residual disease (no pCR) following neoadjuvant chemotherapy, patients with TNBC have the worst prognosis and overall survival. These patients lack the benefit of subsequent targeted therapy. Many studies have addressed improving the efficacy of neoadjuvant chemotherapy by including different cytotoxic agents, biologic modifiers, regimens, and schedules. Up to now, apart from trastuzumab for HRE2/neu+ tumors, none of the targeted agents can be considered a standard therapeutic option for primary systemic treatment. We hereby review the current literature on neoadjuvant chemotherapy for breast cancer, emphasizing treatment of TNBC. We also discuss potentially new therapeutic strategies that target this high risk group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.